Galectin Therapeutics Inc (GALT): Operating Income
-$20.09M
Year ended 2025-12-31
-$15.62M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$20.09M | n/m | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | -$42.43M | n/m | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | -$38.07M | n/m | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | -$38.35M | n/m | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | -$30.18M | n/m | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | -$23.44M | n/m | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | -$13.44M | n/m | 2021-03-31, From 2019-01-01 |
| 2018-12-31 | -$13.60M | n/m | 2020-03-16, From 2018-01-01 |
| 2017-12-31 | -$16.25M | n/m | 2019-03-06, From 2017-01-01 |
| 2016-12-31 | -$21.48M | n/m | 2018-03-29, From 2016-01-01 |
| 2015-12-31 | -$20.08M | n/m | 2017-03-28, From 2015-01-01 |
| 2014-12-31 | -$15.43M | n/m | 2016-03-15, From 2014-01-01 |
| 2013-12-31 | -$12.10M | n/m | 2016-03-15, From 2013-01-01 |
| 2012-12-31 | -$9.90M | n/m | 2015-03-18, From 2012-01-01 |
| 2011-12-31 | -$10.41M | n/m | 2013-03-29, From 2011-01-01 |
| 2010-12-31 | -$4.88M | n/a | 2012-03-30, From 2010-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Galectin Therapeutics Inc (GALT) | 2025-12-31 | -$20.09M | n/m |
| Propanc Biopharma, Inc. (PPCB) | 2025-06-30 | -$57.28M | n/m |
| Lftd Partners Inc. (LIFD) | 2025-12-31 | $913.2K | n/m |
| Marker Therapeutics, Inc. (MRKR) | 2025-12-31 | -$12.89M | n/m |
| Genelux Corp (GNLX) | 2025-12-31 | -$33.21M | n/m |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $3.37M | n/m |
| Nexentis Technologies Inc. (NXTS) | 2025-12-31 | -$4.23M | n/m |
| Incannex Healthcare Inc. (IXHL) | 2025-06-30 | -$23.79M | n/m |
| Jyong Biotech Ltd. (MENS) | 2025-12-31 | -$2.61M | n/m |
Compare GALT, PPCB, LIFD, MRKR side by side · Screen every company in Pharmaceutical Preparations ↗